Showing 1 to 2 of 2 results


CVS Drops Eli Lilly's Zepbound from Preferred Formulary
CVS Health will remove Eli Lilly's weight-loss drug Zepbound from its preferred formulary starting July 1, 2025, prioritizing Novo Nordisk's Wegovy; this impacts 90 million CVS Caremark members and highlights the power of PBMs in shaping drug access and affordability.
CVS Drops Eli Lilly's Zepbound from Preferred Formulary
CVS Health will remove Eli Lilly's weight-loss drug Zepbound from its preferred formulary starting July 1, 2025, prioritizing Novo Nordisk's Wegovy; this impacts 90 million CVS Caremark members and highlights the power of PBMs in shaping drug access and affordability.
Progress
36% Bias Score

Walgreens Considers Breakup, Bucking Healthcare Consolidation Trend
Walgreens Boots Alliance is considering splitting into three companies: Boots UK, U.S. retail pharmacies, and a specialty pharmacy, diverging from the healthcare consolidation trend exemplified by CVS Health's integrated model. This follows Walgreens' financial losses and struggles with its VillageM...

Walgreens Considers Breakup, Bucking Healthcare Consolidation Trend
Walgreens Boots Alliance is considering splitting into three companies: Boots UK, U.S. retail pharmacies, and a specialty pharmacy, diverging from the healthcare consolidation trend exemplified by CVS Health's integrated model. This follows Walgreens' financial losses and struggles with its VillageM...
Progress
48% Bias Score
Showing 1 to 2 of 2 results